These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 36166031)

  • 1. Repurposed Drugs Failed to Prevent Severe COVID-19.
    Slomski A
    JAMA; 2022 Sep; 328(12):1171. PubMed ID: 36166031
    [No Abstract]   [Full Text] [Related]  

  • 2. Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment.
    Martinez MA
    Front Immunol; 2021; 12():635371. PubMed ID: 33777024
    [No Abstract]   [Full Text] [Related]  

  • 3. Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials.
    Paul SS; Biswas G
    Mini Rev Med Chem; 2021; 21(9):1123-1143. PubMed ID: 33355053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational antiviral drugs for the treatment of COVID-19 patients.
    Beheshtirouy S; Khani E; Khiali S; Entezari-Maleki T
    Arch Virol; 2022 Mar; 167(3):751-805. PubMed ID: 35138438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re-purposed antiviral drugs without a purpose in COVID-19: a valuable lesson for clinicians.
    Liuzzo G; Patrono C
    Eur Heart J; 2021 Mar; 42(9):882-883. PubMed ID: 33569601
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.
    Xu J; Xue Y; Zhou R; Shi PY; Li H; Zhou J
    Med Res Rev; 2021 May; 41(3):1375-1426. PubMed ID: 33277927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations.
    Ramakrishnan J; Kandasamy S; Iruthayaraj A; Magudeeswaran S; Chinnasamy K; Poomani K
    Appl Biochem Biotechnol; 2021 Jun; 193(6):1909-1923. PubMed ID: 33512650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic.
    Won JH; Lee H
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33371468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19: Potential Repurposing Drugs.
    Leowattana W
    Infect Disord Drug Targets; 2022; 22(1):e110122191924. PubMed ID: 33645490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of repurposed drugs on the symptomatic COVID-19 patients.
    Hussain I; Hussain A; Alajmi MF; Rehman MT; Amir S
    J Infect Public Health; 2021 Jan; 14(1):24-38. PubMed ID: 33341481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugs repurposing for SARS-CoV-2: new insight of COVID-19 druggability.
    Debnath SK; Debnath M; Srivastava R; Omri A
    Expert Rev Anti Infect Ther; 2022 Sep; 20(9):1187-1204. PubMed ID: 35615888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review.
    Kröker A; Tirzīte M
    Respir Res; 2021 Nov; 22(1):304. PubMed ID: 34838020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug repositioning is an alternative for the treatment of coronavirus COVID-19.
    Serafin MB; Bottega A; Foletto VS; da Rosa TF; Hörner A; Hörner R
    Int J Antimicrob Agents; 2020 Jun; 55(6):105969. PubMed ID: 32278811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulating the host immune response to fight against COVID-19: Where are we in 2021?
    Hertanto DM; Sutanto H; Wiratama BS; Wungu CDK
    Virulence; 2021 Dec; 12(1):1732-1736. PubMed ID: 34224330
    [No Abstract]   [Full Text] [Related]  

  • 15. Application of machine intelligence technology in the detection of vaccines and medicines for SARS-CoV-2.
    Alsharif MH; Alsharif YH; Albreem MA; Jahid A; Solyman AAA; Yahya K; Alomari OA; Hossain MS
    Eur Rev Med Pharmacol Sci; 2020 Nov; 24(22):11977-11981. PubMed ID: 33275275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action.
    Czuppon P; Débarre F; Gonçalves A; Tenaillon O; Perelson AS; Guedj J; Blanquart F
    PLoS Comput Biol; 2021 Mar; 17(3):e1008752. PubMed ID: 33647008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chasing COVID-19 chemotherapeutics without putting the cart before the horse.
    Rannard SP; McDonald TO; Owen A
    Br J Clin Pharmacol; 2023 Jan; 89(1):421-423. PubMed ID: 33217038
    [No Abstract]   [Full Text] [Related]  

  • 18. Repurposed drugs for COVID-19: threshold and proof requirements for trials.
    Paul M; Kalil AC
    Clin Microbiol Infect; 2021 Dec; 27(12):1716-1717. PubMed ID: 34508887
    [No Abstract]   [Full Text] [Related]  

  • 19. COVID-19 Pharmacotherapy: Drug Development, Repurposing of Drugs, and the Role of Pharmacogenomics.
    Bock R; Babayeva M; Loewy ZG
    Methods Mol Biol; 2022; 2547():187-199. PubMed ID: 36068465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tackling SARS-CoV-2: proposed targets and repurposed drugs.
    Joshi S; Joshi M; Degani MS
    Future Med Chem; 2020 Sep; 12(17):1579-1601. PubMed ID: 32564623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.